Elevate your audio experience with the RCA Wave-53 Active Noise Cancelling Wireless Over-Ear Headphones. Designed for audiophiles and everyday users alike, these headphones feature advanced active noise cancelling technology that effectively blocks out ambient noise, allowing you to fully immerse yourself in your favorite music.

2025年1月14日 · 外显子 53 跳跃研究计划 WVE-N531 是一种外显子跳跃寡核苷酸，旨在诱导内源性、功能性肌营养不良蛋白的产生，用于治疗适合进行外显子 53 跳跃的 DMD 男孩。

The RCA Wave-53 headphones are designed with cutting-edge active noise cancelling technology that effectively reduces ambient noise, allowing you to fully immerse yourself in your favorite music. This feature is particularly beneficial in noisy environments, such as airplanes, trains, or busy offices, enabling you to enjoy clear sound without ...

Experience the freedom of undisturbed listening, wherever life takes you. Experience powerful low frequencies with the RCA Wave-53's big bass performance, which enhances your listening experience across a range of music genres.

RCA Wave-55 Wireless Over-Ear Bluetooth Headphones, 40H Playtime, Hi-Resolution Audio

Elevate your audio experience with the RCA Wave-53 Active Noise Cancelling Wireless Over-Ear Headphones. Designed for audiophiles and everyday users alike, these headphones feature advanced active noise cancelling technology that effectively blocks out ambient noise, allowing you to fully immerse yourself in your favorite music.

2025年2月1日 · Wave Life Sciences surges on phase 2 data for exon 53-skipping drug for Duchenne muscular dystrophy that will be discussed with regulators.

2024年8月20日 · WVE-N531 is being evaluated in the open-label Phase 1b/2a FORWARD-53 trial (NCT04906460) that enrolled 11 male patients, ages 5 to 18, at sites in Jordan and the U.K. Results in treatment effects, including dystrophin levels from muscle tissue samples collected after 24 weeks of treatment (about six months), are expected before the end of Septem...

CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...

2024年9月26日 · Newly announced interim data from the phase 2 FORWARD-53 study (NCT04906460) showed that treatment with Wave Life Sciences’ WVE-N531, an investigational antisense oligonucleotide, resulted in substantial dystrophin expression among boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping.